

# A study to evaluate efficacy and safety of obexelimab in patients with IgG4-related disease

<b>Submission date</b> 23/12/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 02/04/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 02/05/2024	<b>Condition category</b> Haematological Disorders	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

IgG4-Related Disease (IgG4-RD) is a rare condition that causes inflammation and scarring in many different areas of the body, including the pancreas, biliary tract, salivary glands and other organs. IgG4-RD can cause different symptoms and affect one or multiple organs. Most patients are middle-aged to elderly men.

The current therapy for IgG4-RD consists of steroids followed by gradual withdrawal. This is initially effective, but 30 to 60% of patients will relapse after discontinued treatment. Long-term steroid therapy can cause several complications. Therefore, there is a need for novel treatment of IgG4-RD.

The purpose of this study is to evaluate the safety and effectiveness of obexelimab, on IgG4-RD. Obexelimab (a B cell targeted therapy) is an investigational drug, which means it has not yet been approved for the treatment of a disease by any regulatory agencies and can only be tested in a study like this one. There have been five studies of obexelimab with a total of 198 healthy volunteers or patients. A Phase 2 study in 20 participants with IgG4-RD showed strong and rapid improvement in their disease activity.

### Who can participate?

Adults aged 18 years and older with a diagnosis of IgG4-RD who are experiencing active signs /symptoms of IgG4-RD

### What does the study involve?

Approximately 200 adult participants are expected to take part globally. After an initial course of steroids, participants will enter a placebo-controlled period (a placebo is an inactive substance which resembles the study drug but has no medical value) where participants will receive obexelimab or placebo as a subcutaneous injection weekly for 52 weeks. At the end of the 52 weeks, participants may enter an open-label extension period, where all participants are given obexelimab for another 52 weeks. All participants will attend a follow-up visit when they complete the study. Study procedures include but are not limited to physical examination, vital signs, CT or MRI scan, blood samples, stool samples, quality of life questionnaires, glucocorticoid treatment and taper.

What are the possible benefits and risks of participating?

Taking part in this study may or may not help to treat your IgG4-RD. Your health could improve, stay the same, or get worse. However, the data we get from you during this study may help doctors learn more about the study drug and whether or not it provides any benefit to patients with IgG4-RD, and this may help future patients with IgG4-RD.

The safety of obexelimab has been studied in 198 people of whom 40 received the subcutaneous injection form used in this study. When obexelimab was given in the intravenous form, there was a serious but uncommon risk for allergic reactions and gastrointestinal symptoms like nausea, vomiting and diarrhea during infusion. Obexelimab treats IgG4-RD by changing your immune system which may cause you risk for infections. When obexelimab was given as the subcutaneous form, there were mild to moderate side effects at the site of injection including redness, pain, and swelling.

Where is the study run from?

Zenas BioPharma (USA) LLC

When is the study starting and how long is it expected to run for?

January 2022 to December 2026

Who is funding the study?

Zenas BioPharma LLC (USA)

Who is the main contact?

Dr Emma Culver, emma.culver@nhs.net

### **Study website**

Link to be included once development of UK website is completed

## **Contact information**

### **Type(s)**

Scientific

### **Contact name**

Dr Maria French

### **Contact details**

1-2 Crown Walk

Jewry Street

Winchester

United Kingdom

SO23 8BB

+44 196 2896764

UKStart-upteam.SM@ppd.com

### **Type(s)**

Principal Investigator

### **Contact name**

Dr Emma Culver

**Contact details**

Headley Way  
Headington  
Oxford  
United Kingdom  
OX3 9DU

-  
emma.culver@nhs.net

**Type(s)**

Scientific

**Contact name**

Dr Allen Poma

**Contact details**

1000 Winter Street  
Waltham  
United States of America  
02451-1438  
+1 (0)857 273 0413  
allen.poma@zenasbio.com

## Additional identifiers

**EudraCT/CTIS number**

2022-500718-24

**IRAS number**

1006349

**ClinicalTrials.gov number**

NCT05662241

**Secondary identifying numbers**

ZB012-03-001, IRAS 1006349, CPMS 54695

## Study information

**Scientific Title**

A Phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obexelimab in patients with IgG4-related disease (INDIGO)

**Acronym**

INDIGO

**Study objectives**

Administration of obexelimab will increase the time to first IgG4-RD flare that requires initiation of rescue therapy.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approval pending, North West - Liverpool Central Research Ethics Committee (+44 (0) 2071048118, +44 (0)20 7104 8222, +44 (0)2071048016; liverpoolcentral.rec@hra.nhs.uk), ref: 23 /NW/0015

**Study design**

Interventional double blind randomized parallel group placebo controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised parallel trial

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details to request a participant information sheet

**Health condition(s) or problem(s) studied**

IgG4-Related Disease

**Interventions**

Participants will be randomised in a 1:1 ratio to receive either obexelimab or placebo as a subcutaneous injection for 52 weeks. At the end of the 52 weeks of the randomized control period (RCP), participants will have the opportunity to continue in an open-label extension period (OLE), where all participants will receive obexelimab. Patients who do not wish to enroll into the open-label extension period will return for an in-clinic safety follow-up visit 8 weeks after the Week 52 visit (i.e., Week 60).

**Intervention Type**

Drug

**Phase**

Phase III

**Drug/device/biological/vaccine name(s)**

Obexelimab

**Primary outcome measure**

Time to first IgG4-RD flare, defined as the reappearance of previous signs/symptoms or appearance of new signs/symptoms of IgG4-RD that requires initiation of rescue therapy in the

opinion of the investigator and the Adjudication Committee (AC), from randomization to Week 52.

### **Secondary outcome measures**

There are no secondary outcome measures

### **Overall study start date**

01/01/2022

### **Completion date**

31/12/2026

## **Eligibility**

### **Key inclusion criteria**

1. Males and females  $\geq 18$  years of age
2. Clinical diagnosis of IgG4-RD
3. Patients must meet the 2019 ACR/EULAR Classification Criteria for IgG4-RD
4. Patients must have active IgG4-RD signs/symptoms (i.e., flare) that require the initiation of GC therapy or the increase in background long-term GC therapy
5. Other inclusion criteria apply

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Sex**

Both

### **Target number of participants**

200

### **Key exclusion criteria**

1. Has disease in only one organ system whose primary manifestation is fibrosis
2. Has received prednisone equivalent given orally at a dose greater than 60 mg/day within the 4 weeks prior to screening or during screening
3. Has received a non-biologic, disease-modifying anti-rheumatological drug or immunosuppressive agent other than GCs within the 4 weeks prior to screening
4. Has received an investigational treatment or direct medical intervention on another clinical study within 12 weeks or  $< 5$  half-lives of the investigational treatment, whichever is shorter, prior to screening
5. Has received live vaccine or live therapeutic infectious agent within the 2 weeks prior to screening
6. Active tuberculosis or high risk for tuberculosis; hepatitis C infection in absence of curative treatment; evidence of hepatitis B infection
7. Use of B cell depleting or targeting agents within 6 months of randomization
8. Other exclusion criteria apply

**Date of first enrolment**

30/09/2022

**Date of final enrolment**

31/12/2024

## **Locations**

**Countries of recruitment**

Argentina

Canada

China

England

France

Germany

Hong Kong

Hungary

Italy

Japan

Korea, South

Mexico

Netherlands

Poland

Spain

Sweden

Taiwan

Türkiye

United Kingdom

United States of America

**Study participating centre**

**John Radcliffe Hospital**

Headley Way  
Headington  
Oxford  
United Kingdom  
OX3 9DU

**Study participating centre****Guys Hospital**

Guys Hospital  
Great Maze Pond  
London  
United Kingdom  
SE1 9RT

**Sponsor information****Organisation**

Zenas BioPharma LLC (USA)

**Sponsor details**

1000 Winter Street  
Waltham  
United States of America  
MA 02451-1436

-

clinicaltrialsinfo@zenasbio.com

**Sponsor type**

Industry

**Funder(s)****Funder type**

Industry

**Funder Name**

Zenas BioPharma LLC (USA)

**Results and Publications**

**Publication and dissemination plan**

Peer reviewed scientific journals

Internal report

Conference presentation

Publication on website

Submission to regulatory authorities

Other

**Intention to publish date**

31/12/2027

**Individual participant data (IPD) sharing plan**

The Sponsor is committed to the responsible sharing of clinical data with the goal of advancing medical science and improving patient care. Independent researchers will be permitted to use anonymised data collected from participants during this study to conduct additional scientific research, which may be unrelated to the study medication. This data will be obtained from study publications once the research has been completed.

The data from study publications will not include identifiable information.

**IPD sharing plan summary**

Published as a supplement to the results publication